A month has gone by since the last earnings report for PDL BioPharma (PDLI - Free Report) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
PDL BioPharma Q3 Earnings Top, Revenues Rise Y/Y
PDL BioPharma reported earnings of 9 cents per share in the third quarter of 2018, lower than year-ago period’s figure of 14 cents.
The company’s total revenues grossed $67.9 million in the reported quarter, reflecting an 8.2% increase year over year. This upside is mainly attributable to a sharp rise in royalties and product revenues.
Quarter in Detail
Product revenues for the quarter under review were $24.4 million, up 21.5% year over year. The same included $17.8 million from the sales of Noden products — Tekturna and Tekturna HCT — and $6.6 million from the sales of LENSAR laser system in the United States.
PDL recognized $42.2 million in revenues from royalty rights, $0.5 million of royalties from PDL's licensees to the Queen et al. patents and $0.8 million of interest revenues.
Royalty revenues from the Queen et al. licenses were lower than the year-ago period, mainly due to weak product supplies of Tysabri.
Research and development (R&D) expenses for the third quarter summed $0.7 million, up 11.1% from the prior-year level. This uptick was owing to a contribution of additional cost of product revenues from Noden products and LENSAR laser system in ex-U.S. markets
General and administrative expenses escalated 10.9% to $13.9 million from the level registered in comparable quarter last year.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
A month has gone by since the last earnings report for PDL BioPharma (PDLI - Free Report) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
PDL BioPharma Q3 Earnings Top, Revenues Rise Y/Y
PDL BioPharma reported earnings of 9 cents per share in the third quarter of 2018, lower than year-ago period’s figure of 14 cents.
The company’s total revenues grossed $67.9 million in the reported quarter, reflecting an 8.2% increase year over year. This upside is mainly attributable to a sharp rise in royalties and product revenues.
Quarter in Detail
Product revenues for the quarter under review were $24.4 million, up 21.5% year over year. The same included $17.8 million from the sales of Noden products — Tekturna and Tekturna HCT — and $6.6 million from the sales of LENSAR laser system in the United States.
PDL recognized $42.2 million in revenues from royalty rights, $0.5 million of royalties from PDL's licensees to the Queen et al. patents and $0.8 million of interest revenues.
Royalty revenues from the Queen et al. licenses were lower than the year-ago period, mainly due to weak product supplies of Tysabri.
Research and development (R&D) expenses for the third quarter summed $0.7 million, up 11.1% from the prior-year level. This uptick was owing to a contribution of additional cost of product revenues from Noden products and LENSAR laser system in ex-U.S. markets
General and administrative expenses escalated 10.9% to $13.9 million from the level registered in comparable quarter last year.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PDLI - FREE